Clinical trials: Oligometastasis
Advanced Hepatocellular Carcinoma, Lung Cancer
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical…
- Conditions
- Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis, Ablation
- Trial name
- NCT06644430
- Testing
- Ablation, system therapy
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer, Oligometastasis
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate…
- Conditions
- Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer
- Trial name
- VA STARPORT (NCT04787744)
- Testing
- PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease
- Where
- 20 sites in United States
- Volunteers
- 378 people
- Sponsor
- VA Office of Research and Development
Breast Cancer, Oligometastasis
Metastasis-directed Therapy for Oligometastases of Breast Cancer
OLIGAMI trial is a multi-institutional, two-arm, open-label, randomized controlled phase III trial being conducted with the participation of 50 hospitals belonging to Japan Clinical Oncology Group.
- Conditions
- Breast Cancer, Oligometastasis, Metastatic Breast Cancer
- Trial name
- OLIGAMI (NCT06135714)
- Testing
- Systemic therapy for 12 weeks after primary registration, Radiation therapy (SBRT/conventional RT), Surgery
- Where
- Japan
- Volunteers
- 146 people
- Sponsor
- Tokyo Medical and Dental University
Gastric Adenocarcinoma, Oligometastasis
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
This phase II trial studies how well chemotherapy with or without radiation or surgery works in treating participants with esophageal or gastric cancer that has spread to less than 3 places in the body (oligometastatic).
- Conditions
- Gastric Adenocarcinoma, Oligometastasis, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Cancer AJCC v7
- Trial name
- NCT03161522
- Testing
- Capecitabine, Chemotherapy, Conventional Surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer, Stage IV
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy plus stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the locoregional primary tumour, in…
- Conditions
- Non-small Cell Lung Cancer, Stage IV, Oligometastasis
- Trial name
- CHESS (NCT03965468)
- Testing
- Durvalumab, Carboplatin, Paclitaxel
- Where
- 14 sites in Italy, Netherlands and 2 more
- Volunteers
- 96 people
- Sponsor
- ETOP IBCSG Partners Foundation
Oligometastasis, Oligometastatic Disease
Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)
This study is for participants whose cancer is oligometastatic, meaning it has spread to up to five spots in their body and their doctor recommends that they have stereotactic body radiation therapy (SBRT) to treat these cancer…
- Trial name
- NCT07079098
- Testing
- Simulation-free workflow, SBRT
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
This phase II trial studies how well surgery and radiation therapy work in treating patients with prostate cancer that has come back or spread to other parts of the body.
- Conditions
- Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Oligometastasis
- Trial name
- SOAR (NCT03796767)
- Testing
- Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Metastasectomy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Bladder Cancer, Urothelial Carcinoma (UC)
Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA
Bladder cancer is the most common type of urothelial cancer. When the disease has spread to other parts of the body (metastatic disease), the prognosis is often poor, because there are only a few effective treatment options…
- Conditions
- Bladder Cancer, Urothelial Carcinoma (UC), Oligometastasis
- Trial name
- ASTRA (NCT07413523)
- Testing
- SBRT
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Istituto Clinico Humanitas
Breast Cancer, Oligometastasis
stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database
Oligometastatic breast cancer is a condition in which breast cancer has spread to a small number of other parts of the body. Patients with this type of disease may live longer than those with more widespread metastases.
- Trial name
- ORIETTA (NCT07397585)
- Where
- 28 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Istituto Clinico Humanitas
Oligometastasis, Metastatic Cancer
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
- Trial name
- NCT04085029
- Where
- 5 sites in United States
- Volunteers
- 300 people
- Sponsor
- Duke University
Oligometastasis, Lung Cancer
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients…
- Conditions
- Oligometastasis, Lung Cancer, Colo-rectal Cancer, Prostate Cancer
- Trial name
- ID-COMET (NCT06563388)
- Testing
- Stereotactic Ablative Radiotherapy, Best Practice
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer, Oligometastasis
Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients
Metastatic prostate cancer has traditionally been regarded as an incurable dissemination of disease, and treatment is focused on delaying progression rather than eliminating all tumor burden.
- Trial name
- OLIGOPELVIS2 (NCT03630666)
- Testing
- IADT, IADT + radiotherapy
- Where
- 16 sites in France
- Volunteers
- 256 people
- Sponsor
- Institut Cancerologie de l'Ouest
Stereotactic Body Radiation Therapy (SBRT), Oligometastasis
SMC Radiation Oncology SABR Cohort for Oligometastasis
The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1.
- Conditions
- Stereotactic Body Radiation Therapy (SBRT), Oligometastasis, Oligoprogression, ctDNA
- Trial name
- SABR-OMOP (NCT07121335)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Gynecologic Cancer, Skin Cancer
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers.
- Conditions
- Gynecologic Cancer, Skin Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- OligoRARE (NCT04498767)
- Testing
- Stereotactic body radiotherapy, Palliative RT
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Hepatocellular Carcinoma, Oligometastasis
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
Ablation has been an effective approach for treating intrathoracic metastases. However, for hepatocellular carcinoma with oligometastasis, ablation of metastases remains relatively unexplored.
- Conditions
- Advanced Hepatocellular Carcinoma, Oligometastasis, Ablation, Anti-PD1 Antibody
- Trial name
- NCT06550921
- Testing
- ablation of oligometastasis
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer, Prostate Cancer Recurrent
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed…
- Conditions
- Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic, Metastatic Cancer
- Trial name
- SPARKLE (NCT05352178)
- Testing
- Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy
- Where
- Belgium
- Volunteers
- 873 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
PSMA-PET/CT or PSMA-PET/MRI are more accurate imaging modalities compared to CT/BS; in approximately 10-20% of high-risk patients diagnosed using conventional imaging PSMA-PET up-stages the disease.
- Conditions
- Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone, Prostate Cancer, Prostate Neoplasm
- Trial name
- OLIGOMET (NCT06430411)
- Testing
- Radical prostatectomy, Prostate irradiation, Surgical metastasectomy
- Volunteers
- 500 people
- Sponsor
- Medical University of Vienna
Prostate Cancer, Prostate Cancer Recurrent
Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer
The current trial will test the combination of darolutamide with SBRT, in oligometastatic recurrent hormone sensitive prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic, Metastatic Cancer
- Trial name
- DART (NCT04641078)
- Testing
- Darolutamide, metastasis-directed treatment
- Where
- 8 sites in Belgium
- Volunteers
- 124 people
- Sponsor
- University Hospital, Ghent
Nasopharyngeal Carcinoma, Oligometastasis
Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma
The main purpose of this study is to see how well the experimental drug camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally radiotherapy for their disease.
- Conditions
- Nasopharyngeal Carcinoma, Oligometastasis, Radiotherapy
- Trial name
- NCT04221516
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Oligometastasis Hepatocellular Carcinoma
Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma
Oligometastasis is a definition that has been described in the past in the 1990s, and in some patients, metastases are not extensive and are limited to a small number of metastases.
- Trial name
- NCT05173610
- Testing
- Radiation: Stereotactic body radiotherapy (SBRT)
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University